The results showed that SCP2 significantly reversed the metabolic profile disorder in Alzheimer’s disease rats and played an important role in ameliorating Aβ25-35-induced cognitive dysfunction, attenuating oxidative damage, and reducing Aβ deposition in the hippocampus, which may provide new insight into the potential mechanisms of SCP2 treatment of AD (119). Here, SCP2 is linked to Alzheimer disease.